Skip to main content
. Author manuscript; available in PMC: 2017 Feb 20.
Published in final edited form as: Clin Cancer Res. 2011 Feb 8;17(4):888–895. doi: 10.1158/1078-0432.CCR-10-1706

Table 2.

Summary of adverse events*

Toxicity Small cell carcinoma Mixed neuroendocrine
107 vp/kg
N = 6		 107–1010 vp/kg
N = 12		 1011 vp/kg
N = 12
Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3 Grade 1 Grade 2 Grade 3
Pyrexia 2 (33%) 1 (17%) 0 4 (33%) 0 0 4 (33%) 1 (8%) 0
Fatigue 0 0 0 5 (42%) 1 (8%) 0 2 (17%) 1 (8%) 0
Headache 0 0 0 2 (17%) 1 (8%) 0 0 1 (8%) 0
Lymphopenia 0 0 0 0 0 0 0 1 (8%) 1 (8%)
Muscle spasms 0 0 0 0 0 0 0 1 (8%) 0
Cough 0 0 0 0 0 0 0 1 (8%) 0
*

All toxicities that reached CTCAE grade ≥2 in at least 1 study subject. For these toxicites, number of grade 1 events is also reported.